These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 18303084)

  • 61. Placenta growth factor and vascular endothelial growth factor B expression in the hypoxic lung.
    Sands M; Howell K; Costello CM; McLoughlin P
    Respir Res; 2011 Jan; 12(1):17. PubMed ID: 21266048
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Inhibition of the Ras/Raf/MEK/ERK and RET kinase pathways with the combination of the multikinase inhibitor sorafenib and the farnesyltransferase inhibitor tipifarnib in medullary and differentiated thyroid malignancies.
    Hong DS; Cabanillas ME; Wheler J; Naing A; Tsimberidou AM; Ye L; Busaidy NL; Waguespack SG; Hernandez M; El Naggar AK; Bidyasar S; Wright J; Sherman SI; Kurzrock R
    J Clin Endocrinol Metab; 2011 Apr; 96(4):997-1005. PubMed ID: 21289252
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Sorafenib inhibits activation of human peripheral blood T cells by targeting LCK phosphorylation.
    Zhao W; Gu YH; Song R; Qu BQ; Xu Q
    Leukemia; 2008 Jun; 22(6):1226-33. PubMed ID: 18337760
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Sorafenib exerts anti-glioma activity in vitro and in vivo.
    Siegelin MD; Raskett CM; Gilbert CA; Ross AH; Altieri DC
    Neurosci Lett; 2010 Jul; 478(3):165-70. PubMed ID: 20470863
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Everolimus augments the effects of sorafenib in a syngeneic orthotopic model of hepatocellular carcinoma.
    Piguet AC; Saar B; Hlushchuk R; St-Pierre MV; McSheehy PM; Radojevic V; Afthinos M; Terracciano L; Djonov V; Dufour JF
    Mol Cancer Ther; 2011 Jun; 10(6):1007-17. PubMed ID: 21487053
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Synergistic activity of letrozole and sorafenib on breast cancer cells.
    Bonelli MA; Fumarola C; Alfieri RR; La Monica S; Cavazzoni A; Galetti M; Gatti R; Belletti S; Harris AL; Fox SB; Evans DB; Dowsett M; Martin LA; Bottini A; Generali D; Petronini PG
    Breast Cancer Res Treat; 2010 Nov; 124(1):79-88. PubMed ID: 20054642
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Sorafenib combined vitamin K induces apoptosis in human pancreatic cancer cell lines through RAF/MEK/ERK and c-Jun NH2-terminal kinase pathways.
    Wei G; Wang M; Carr BI
    J Cell Physiol; 2010 Jul; 224(1):112-9. PubMed ID: 20301194
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Downregulation of type II bone morphogenetic protein receptor in hypoxic pulmonary hypertension.
    Takahashi H; Goto N; Kojima Y; Tsuda Y; Morio Y; Muramatsu M; Fukuchi Y
    Am J Physiol Lung Cell Mol Physiol; 2006 Mar; 290(3):L450-8. PubMed ID: 16361357
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Sorafenib protects human optic nerve head astrocytes from light-induced overexpression of vascular endothelial growth factor, platelet-derived growth factor, and placenta growth factor.
    Kernt M; Liegl RG; Rueping J; Neubauer AS; Haritoglou C; Lackerbauer CA; Eibl KH; Ulbig MW; Kampik A
    Growth Factors; 2010 Jun; 28(3):211-20. PubMed ID: 20166888
    [TBL] [Abstract][Full Text] [Related]  

  • 70. The monoclonal antibody CH12 enhances the sorafenib-mediated growth inhibition of hepatocellular carcinoma xenografts expressing epidermal growth factor receptor variant III.
    Yang Y; Jiang H; Gao H; Kong J; Zhang P; Hu S; Shi B; Zhang P; Yao M; Li Z
    Neoplasia; 2012 Jun; 14(6):509-18. PubMed ID: 22787432
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Treatment effects of the multikinase inhibitor sorafenib on hepatoblastoma cell lines and xenografts in NMRI-Foxn1 nu mice.
    Eicher C; Dewerth A; Kirchner B; Warmann SW; Fuchs J; Armeanu-Ebinger S
    Liver Int; 2012 Apr; 32(4):574-81. PubMed ID: 22176637
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Hypoxia-inducible factor-1 α/platelet derived growth factor axis in HIV-associated pulmonary vascular remodeling.
    Mermis J; Gu H; Xue B; Li F; Tawfik O; Buch S; Bartolome S; O'Brien-Ladner A; Dhillon NK
    Respir Res; 2011 Aug; 12(1):103. PubMed ID: 21819559
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Validation of VX2 as a Hepatocellular Carcinoma Model: Comparison of the Molecular Reaction of VX2 and HepG2 Tumor Cells to Sorafenib In Vitro.
    Nass N; Streit S; Wybranski C; Jürgens J; Brauner J; Schulz N; Powerski M; Ricke J; Kalinski T; Dudeck O; Seidensticker M
    Anticancer Res; 2017 Jan; 37(1):87-93. PubMed ID: 28011478
    [TBL] [Abstract][Full Text] [Related]  

  • 74. STAT3-mediated attenuation of CCl4-induced mouse liver fibrosis by the protein kinase inhibitor sorafenib.
    Deng YR; Ma HD; Tsuneyama K; Yang W; Wang YH; Lu FT; Liu CH; Liu P; He XS; Diehl AM; Gershwin ME; Lian ZX
    J Autoimmun; 2013 Oct; 46():25-34. PubMed ID: 23948302
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Sorafenib (BAY 43-9006, Nexavar), a dual-action inhibitor that targets RAF/MEK/ERK pathway in tumor cells and tyrosine kinases VEGFR/PDGFR in tumor vasculature.
    Adnane L; Trail PA; Taylor I; Wilhelm SM
    Methods Enzymol; 2006; 407():597-612. PubMed ID: 16757355
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Brivanib, a dual FGF/VEGF inhibitor, is active both first and second line against mouse pancreatic neuroendocrine tumors developing adaptive/evasive resistance to VEGF inhibition.
    Allen E; Walters IB; Hanahan D
    Clin Cancer Res; 2011 Aug; 17(16):5299-310. PubMed ID: 21622725
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Sorafenib, a dual Raf kinase/vascular endothelial growth factor receptor inhibitor has significant anti-myeloma activity and synergizes with common anti-myeloma drugs.
    Ramakrishnan V; Timm M; Haug JL; Kimlinger TK; Wellik LE; Witzig TE; Rajkumar SV; Adjei AA; Kumar S
    Oncogene; 2010 Feb; 29(8):1190-202. PubMed ID: 19935717
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Combination of hypoxia and RNA-interference targeting VEGF induces apoptosis in hepatoma cells via autocrine mechanisms.
    Raskopf E; Vogt A; Decker G; Hirt S; Daskalow K; Cramer T; Standop J; Gonzalez-Carmona MA; Sauerbruch T; Schmitz V
    Curr Pharm Biotechnol; 2012 Sep; 13(11):2290-8. PubMed ID: 21605070
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Lysyl oxidases play a causal role in vascular remodeling in clinical and experimental pulmonary arterial hypertension.
    Nave AH; Mižíková I; Niess G; Steenbock H; Reichenberger F; Talavera ML; Veit F; Herold S; Mayer K; Vadász I; Weissmann N; Seeger W; Brinckmann J; Morty RE
    Arterioscler Thromb Vasc Biol; 2014 Jul; 34(7):1446-58. PubMed ID: 24833797
    [TBL] [Abstract][Full Text] [Related]  

  • 80. The Short-Chain Fatty Acid Butyrate Attenuates Pulmonary Vascular Remodeling and Inflammation in Hypoxia-Induced Pulmonary Hypertension.
    Karoor V; Strassheim D; Sullivan T; Verin A; Umapathy NS; Dempsey EC; Frank DN; Stenmark KR; Gerasimovskaya E
    Int J Mol Sci; 2021 Sep; 22(18):. PubMed ID: 34576081
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.